| 10:00 am 128 |
Vaginal Application of a Small Molecule CCR5 Inhibitor Protects Macaques against Vaginal SHIV 162P Transmission
Ronald Veazey*1, P Klasse2, J Dufour1, M Springer3, and J Moore2
1Tulane Natl Primate Res Ctr, Tulane Univ, Covington, LA, USA; 2Weill Med Coll, Cornell Univ, New York, NY, USA; and 3Merck Res Labs, Rahway, NJ, USA |
| 10:15 am 129 |
Microbicidal Potential of RNA Interference in vivo
Patricia Cristofaro*1 and B Ramratnam1
1Brown Univ, Providence, RI, USA |
| 10:30 am 130 |
A Novel HIV-1-Neutralizing Antibody That Targets a Highly Conserved Region of the Viral Fusion Machinery
Romas Geleziunas*1, A Pessi2, E Bianchi2, G Barbato2, R Hrin1, M Lu1, H Zhang1, S Lennard3, D Lowe3, P Ingallinella2, G Ciliberto2, R Cortese2, D Hazuda1, J Shiver1, and M Miller1
1Merck Res Labs, West Point, PA, USA; 2IRBM 'P Angeletti', Rome, Italy; and 3Cambridge Antibody Tech, UK |
| 10:45 am 131 |
Dynamic Immune Responses Maintain Cytotoxic T-Lymphocyte Epitope Mutations in Transmitted SIV Variants
Dan Barouch*1, J Powers2, F Peyerl1, M Kuroda1, V Hirsch3, D Montefiori4, A Carville5, K Mansfield5, K Kunstman2, S Wolinksy2, and N Letvin1
1Beth Israel Deaconess Med Ctr and Harvard Med Sch, Boston, MA, USA; 2Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA; 3NIAID, NIH, DHHS, Rockville, MD, USA; 4Duke Univ Med Ctr, Durham, NC, USA; and 5New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, USA |
| 11:00 am 132 |
Control of Viremia after Antiretroviral Treatment and Therapeutic Vaccination with Novel Forms of DNA Vaccines in Chronically SIVmac251-infected Macaques
B Felber1, A von Gegerfelt1, M Rosati1, C Alicea1, P Roth1, J Bear1, A Valentin1, J Boyer2, D Weiner2, N Bischofberger3, P Markham4, P Albert5, G Franchini5, and George Pavlakis*1
1NCI-Frederick, NIH, DHHS, MD, USA; 2Univ of Pennsylvania, Philadelphia, USA; 3Gilead, Foster City, CA, USA; 4Advanced BioSciences Laboratories, Inc., Kensington, MD, USA; and 5NCI, NIH, DHHS, Bethesda, MD, USA |
| 11:15 am 133LB |
Sustained Control of Viremia following Therapeutic Immunization in Chronically HIV-1-infected Individuals: Long-term Follow-up of the ANRS 093 Trial
Yves Levy*1, C Durier2, V Meiffredy2, H Gahery-Segard3, A S Lascaux1, C Goujard4, J P Cassuto5, C Rouzioux6, R El Habib7, M Beumont-Mauviel8, J G Guillet3, M Kazatchkine9, J F Delfraissy4, J P Aboulker2, and ANRS 093 Study Group, ANRS, Paris, France
1Henri Mondor Hosp, Créteil, France; 2INSERM SC10, Villejuif, France; 3INSERM U567, Paris, France; 4Hosp. Bicêtre, Kremlin-Bicêtre, France; 5Hosp. Archet, Nice, France; 6Ctr Hosp Univ Necker, Paris, France; 7Aventis Pasteur, Marcy l'Etoile, France; 8Laboratoire Chiron, Suresnes, France; and 9Hosp. Européen G. Pompidou and ANRS, Paris, France |
| 11:30 am 134 |
Immunization of Rhesus Monkeys with a Multi-gene HIV-1 DNA/MVA Vaccine Provides Protection from Systemic Infection after Repeated Low-dose Intrarectal SHIV Heterologous Challenge
Salvatore Butera*1, D Ellenberger1, L Wyatt2, B Li1, S Buge1, I Rodriguez3, C Sariol3, M Martinez3, A Greenberg1, E Kraiselburd3, B Moss2, H Robinson4, J McNicholl1, R Otten1, and T Folks1
1CDC, Atlanta, GA, USA; 2NIAID, Bethesda, MD, USA; 3Caribbean Primate Res Ctr, San Juan, Puerto Rico; and 4Emory Univ, Atlanta, GA, USA |
| 11:45 am 135 |
Safety and Immunogenicity of the MRK Adenovirus Type-5 gag/pol/nef HIV-1 (Trivalent) Vaccine in Healthy Adults
Frances Priddy*1, D Wright2, J Lalezari3, S Santiago4, R Novak5, S Brown6, M Lally7, M Marmor8, J Kublin9, R Leavitt10, R Isaacs10, D Mehrotra10, J Shiver10, D Brown10, and V520 Protocol 016 Study Group
1Emory Univ Vaccine Res Ctr, Decatur, GA, USA; 2Central Texas Clin Res, Austin, USA; 3Quest Clin Res, San Francisco, CA, USA; 4Care Resource, Miami, FL, USA; 5Univ of Illinois at Chicago, USA; 6AIDS Res Alliance, West Hollywood, CA, USA; 7Brown Univ, Providence, RI, USA; 8New York Univ Sch of Med, NY, USA; 9Fred Hutchinson Cancer Res Ctr, Seattle, WA, USA; and 10Merck Res Labs, West Point, PA, USA |
| 12:00 pm 136LB |
Chemoprophylaxis with Oral Tenofovir Disoproxil Fumarate (TDF) Delays but Does Not Prevent Infection in Rhesus Macaques Given Repeated Rectal Challenges of SHIV
Shambavi Subbarao*, R Otten, A Ramos, E Jackson, D Adams, C Kim, S Bashirian, J Johnson, M Monsour, R Janssen, L Paxton, A Greenberg, and T Folks
CDC, Atlanta, GA, USA |
12:15 pm 136
 |
Pre-Exposure Prophylaxis
Robert M Grant
Gladstone Inst of Virology and Immunology, Univ of California, San Francisco, USA |
